SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief scientific officer, and Tran will lead HR efforts as chief people officer. Both will report to Xaira CEO Marc Tessier-Lavigne.

加利福尼亚州南旧金山（商业新闻短讯）--Xaira Therapeutics今天宣布任命Debbie Law博士和Julia Tran为其C-suite。Law将担任首席科学官，Tran将作为首席人力资源官领导人力资源工作。双方都将向Xaira首席执行官马克·特西尔·拉维尼（MarcTessierLavigne）汇报工作。

Xaira Therapeutics launched in April on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH and Foresite Labs, Xaira launched with more than $1 billion of committed capital from lead investors ARCH Venture Partners and Foresite Capital, joined by F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, Rsquared, and SV Angel, among others..

Xaira Therapeutics于4月启动，其使命是通过新兴人工智能技术的端到端应用，帮助我们重新设计发现和开发药物的方式。作为ARCH和Foresite实验室的联合孵化，Xaira从主要投资者ARCH Venture Partners和Foresite capital那里获得了超过10亿美元的承诺资本，加入了F-Prime、NEA、红杉资本、Lux capital、Lightspeed Venture Partners、Menlo Ventures、Two Sigma Ventures、Parker Institute for Cancer Immunotherapy（PICI）、Byers capital、Rsquared和SV Angel等。。

“Since our launch in April, we have made important progress towards our ambitious goals,” said Marc Tessier-Lavigne. “The hiring of Debbie and Julia as C-suite appointments is another significant step forward, and I’m thrilled to have the opportunity to work with such a high caliber team.”

马克·特西尔·拉维尼（MarcTessierLavigne）说：“自4月份推出以来，我们在实现宏伟目标方面取得了重要进展。“聘用黛比和茱莉亚担任高级管理人员是又向前迈出的重要一步，我很高兴有机会与如此高素质的团队合作。”

Since launch, Xaira has been building AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. The company was co-founded by Nobel Laureate Dr. David Baker from the Institute for Protein Design at the University of Washington and employs a team of researchers from Dr.

自推出以来，Xaira一直在构建AI研究能力，涵盖基本计算方法的开发及其在生物发现，药物样物质设计和临床开发中的应用。该公司是由华盛顿大学蛋白质设计研究所的诺贝尔奖获得者大卫·贝克博士共同创立的，并聘请了一支来自。

Baker’s lab that developed the leading models for protein and antibody design, RFdiffusion and RFantibody. Last week Dr. Baker was awarded the 2024 Nobel Prize in Chemistry together with Drs. Demis Hassabis and John Jumper of Google DeepMind for their breakthroughs in using AI to enable prediction of protein structure and in extending this to the design of novel proteins.

贝克实验室开发了蛋白质和抗体设计，RFdiffusion和RFantibody的领先模型。上周，贝克博士与谷歌DeepMind的Demis Hassabis博士和John Jumper博士一起获得了2024年诺贝尔化学奖，因为他们在使用人工智能预测蛋白质结构以及将其扩展到新型蛋白质设计方面取得了突破。

The Xaira team is working to advance these models and develop new methods that can connect the world of biological targets and engineered molecules to the human experience of disease..

Xaira团队正在努力推进这些模型，并开发新方法，将生物靶标和工程分子的世界与人类的疾病体验联系起来。。

Law most recently served as senior vice president and head of Bristol Myers Squibb’s Non-clinical Research and Discovery Biotherapeutics organizations. Prior to BMS, she held positions of leadership at pharmaceutical companies Janssen and Merck, and served as CSO at biotech firms Jounce Therapeutics and Ablynx NV.

Law最近担任百时美施贵宝非临床研究和发现生物治疗组织的高级副总裁兼负责人。在加入BMS之前，她曾在杨森和默克制药公司担任领导职务，并在生物技术公司Jounce Therapeutics和Ablynx NV担任CSO。

She obtained a Doctor of Philosophy (DPhil) degree in immunology from the University of Oxford, and completed postdoctoral studies at UCSF..

她获得了牛津大学免疫学博士学位，并在UCSF完成了博士后研究。。

“I couldn't be more delighted to join Xaira,” said Law. “My background and interests dovetail perfectly with Xaira’s ambitious mission, and I am looking forward to working with this team as we develop and leverage innovative technologies to bring new therapeutics to patients.”

“我非常高兴能加入哈拉，”劳说。“我的背景和兴趣与Xaira的雄心勃勃的使命非常吻合，我期待着与这个团队合作，开发和利用创新技术为患者带来新的治疗方法。”

With more than 25 years of experience, Julia Tran has played a pivotal role in scaling high-growth biotech and tech companies from early-stage development through commercialization, IPOs and M&As, on both the East and West Coasts. She most recently served as chief people officer at Graphite Bio, and prior to that she co-founded a cyber security company.

凭借超过25年的经验，Julia Tran在东西海岸从早期发展到商业化、IPO和并购的高增长生物技术和科技公司的规模扩张中发挥了关键作用。她最近担任Graphite Bio的首席人事官，在此之前，她与人共同创立了一家网络安全公司。

Her career spans many facets of biotech HR, including at Millennium Pharmaceuticals, Amyris Biotechnologies and CV Therapeutics..

她的职业生涯跨越了生物技术人力资源的许多方面，包括在千禧制药公司、Amyris Biotechnologies和CV Therapeutics。。

“There is no place I'd rather be,' said Tran. 'We have an incredible opportunity to bring together diverse talents and capabilities from the worlds of biotech and tech to rethink how we can help patients, and it's an immense honor to be here.”

“我不想去任何地方，”Tran说。“我们有一个令人难以置信的机会，汇集来自生物技术和技术领域的各种人才和能力，重新思考我们如何帮助患者，来到这里是一种莫大的荣誉。”

Xaira is led by renowned scientist Dr. Marc Tessier-Lavigne, former Chief Scientific Officer of Genentech and former President of Rockefeller and Stanford Universities. Other senior executives include co-founder Dr. Hetu Kamisetty, formerly of Meta and the Institute for Protein Design; Dr. Arvind Rajpal, formerly of Genentech; and Dr.

Xaira由著名科学家MarcTessierLavigne博士领导，他是基因泰克（Genentech）前首席科学官、洛克菲勒大学（Rockefeller）和斯坦福大学（Stanford University）前校长。其他高级管理人员包括联合创始人Hetu Kamisetty博士，前Meta和蛋白质设计研究所；Arvind Rajpal博士，前基因泰克公司；。

Don Kirkpatrick, formerly of Interline and Genentech..

唐·柯克帕特里克（DonKirkpatrick），曾任职于Interline和Genentech。。

About Xaira Therapeutics

关于Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease.

。该公司试图通过汇集三个核心领域的领先人才，从端到端重新思考药物发现和开发过程：机器学习研究以更好地理解生物学，扩展数据生成以支持新模型，以及强大的治疗产品开发以治疗疾病。

Xaira is headquartered in the San Francisco Bay Area..

Xaira总部位于旧金山湾区。。